Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results

P Pfeiffer; B Glimelius; S Winther; C Qvortrup; M. Yilmaz; A Berglund; K Vistisen; C  Kersten; G Liposits; H Sorbye

doi:10.1093/annonc/mdz154.014

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results

P Pfeiffer, B Glimelius, S Winther, C Qvortrup, M. Yilmaz, A Berglund, K Vistisen, C Kersten, G Liposits, H Sorbye

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	mdz154.014
Journal	Annals of Oncology
Volume	30
Issue number	Suppl. 4
Pages (from-to)	iv131-iv131
Number of pages	1
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdz154.014
Publication status	Published - 2019
Event	ESMO World Congress on Gastrointestinal Cancer 2019 - Barcelona, Spain Duration: 3 Jul 2019 → 6 Jul 2019 Conference number: 21 https://www.esmo.org/Conferences/ESMO-World-GI-2019

Conference

Conference	ESMO World Congress on Gastrointestinal Cancer 2019
Number	21
Country/Territory	Spain
City	Barcelona
Period	03/07/2019 → 06/07/2019
Internet address	https://www.esmo.org/Conferences/ESMO-World-GI-2019

Access to Document

10.1093/annonc/mdz154.014

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Pfeiffer, P., Glimelius, B., Winther, S., Qvortrup, C., Yilmaz, M., Berglund, A., Vistisen, K., Kersten, C., Liposits, G., & Sorbye, H. (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology, 30(Suppl. 4), iv131-iv131. Article mdz154.014. https://doi.org/10.1093/annonc/mdz154.014

@article{10495a3c9b2144d99628d03005f930b3,

title = "Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results",

author = "P Pfeiffer and B Glimelius and S Winther and C Qvortrup and M. Yilmaz and A Berglund and K Vistisen and C Kersten and G Liposits and H Sorbye",

year = "2019",

doi = "10.1093/annonc/mdz154.014",

language = "English",

volume = "30",

pages = "iv131--iv131",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl. 4",

note = "ESMO World Congress on Gastrointestinal Cancer 2019<br/>, ESMO19 ; Conference date: 03-07-2019 Through 06-07-2019",

url = "https://www.esmo.org/Conferences/ESMO-World-GI-2019",

}

Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, A, Vistisen, K, Kersten, C, Liposits, G & Sorbye, H 2019, 'Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results', Annals of Oncology, vol. 30, no. Suppl. 4, mdz154.014, pp. iv131-iv131. https://doi.org/10.1093/annonc/mdz154.014

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. / Pfeiffer, P; Glimelius, B; Winther, S et al.
In: Annals of Oncology, Vol. 30, No. Suppl. 4, mdz154.014, 2019, p. iv131-iv131.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

T2 - ESMO World Congress on Gastrointestinal Cancer 2019<br/>

AU - Pfeiffer, P

AU - Glimelius, B

AU - Winther, S

AU - Qvortrup, C

AU - Yilmaz, M.

AU - Berglund, A

AU - Vistisen, K

AU - Kersten, C

AU - Liposits, G

AU - Sorbye, H

N1 - Conference code: 21

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz154.014

DO - 10.1093/annonc/mdz154.014

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

SP - iv131-iv131

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 4

M1 - mdz154.014

Y2 - 3 July 2019 through 6 July 2019

ER -